KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBT: 2009-2024

Historic EBT for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $470.4 million.

  • Jazz Pharmaceuticals' EBT fell 95.50% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.2 million, marking a year-over-year decrease of 41.49%. This contributed to the annual value of $470.4 million for FY2024, which is 57.87% up from last year.
  • As of FY2024, Jazz Pharmaceuticals' EBT stood at $470.4 million, which was up 57.87% from $297.9 million recorded in FY2023.
  • Jazz Pharmaceuticals' EBT's 5-year high stood at $470.4 million during FY2024, with a 5-year trough of -$372.8 million in FY2022.
  • Over the past 3 years, Jazz Pharmaceuticals' median EBT value was $297.9 million (recorded in 2023), while the average stood at $131.8 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' EBT tumbled by 230.37% in 2022, and later soared by 179.92% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' EBT (Yearly) stood at $275.1 million in 2020, then slumped by 141.02% to -$112.8 million in 2021, then plummeted by 230.37% to -$372.8 million in 2022, then soared by 179.92% to $297.9 million in 2023, then surged by 57.87% to $470.4 million in 2024.